What is the recommended injectable glucagon dose for treating sulfonylurea‑induced hypoglycemia?

Injectable Glucagon Dose for Sulfonylurea-Induced Hypoglycemia

For sulfonylurea-induced hypoglycemia in adults and children weighing more than 44 lb (20 kg), administer 1 mg of glucagon by subcutaneous, intramuscular, or intravenous injection; for children weighing less than 44 lb (20 kg), give 0.5 mg (or 20-30 mcg/kg). 1

Dosing Algorithm

Adults and Children >20 kg (>44 lb):

• Initial dose: 1 mg subcutaneous, intramuscular, or intravenous
• Expect response within 5-15 minutes 2
• If no response after 15 minutes, repeat 1 mg dose 1
• After patient awakens, provide supplemental carbohydrates to restore liver glycogen and prevent secondary hypoglycemia 1

Children <20 kg (<44 lb):

• Initial dose: 0.5 mg (or 20-30 mcg/kg) subcutaneous, intramuscular, or intravenous 1
• Alternative dosing: 30 mcg/kg up to maximum 1 mg 2
• Lower dose of 10 mcg/kg results in similar blood glucose at 20 minutes with less nausea 2

Critical Considerations for Sulfonylurea-Induced Hypoglycemia

Sulfonylurea-induced hypoglycemia is particularly dangerous because it can be prolonged and recurrent. Unlike insulin-induced hypoglycemia, sulfonylureas stimulate endogenous insulin secretion for extended periods, often requiring:

• Prolonged observation (24-48 hours minimum) even after initial recovery
• Continuous IV dextrose infusion may be necessary for sustained periods 3
• Repeated glucagon doses may be needed as hypoglycemia recurs 1
• Hospital admission is typically warranted, especially for long-acting agents like chlorpropamide and glyburide 3

Important Pitfalls

Do not assume a single glucagon dose will suffice. Sulfonylureas, particularly chlorpropamide and glyburide, account for 63% of drug-induced hypoglycemia cases and frequently cause prolonged, recurrent episodes 3. The patient may initially respond to glucagon but develop recurrent hypoglycemia hours later as the sulfonylurea continues to stimulate insulin release.

Position the patient on their side before administering glucagon to prevent aspiration, as nausea and vomiting are common side effects occurring in most patients 1.

Intravenous dextrose is preferred over glucagon when IV access is available 4. Glucagon has a slower response (achieving final blood glucose of 167 mg/dL after 140 minutes) compared to IV dextrose (14-170 mg/dL increase in first 10 minutes) 4.

Preparation and Administration

• Reconstitute lyophilized glucagon with provided diluent immediately before use 1
• Use only if solution is clear and water-like in consistency 1
• Discard any unused portion 1
• Glucagon should not be used at concentrations greater than 1 mg/mL 1

Post-Treatment Management

After glucagon administration and patient awakening:

1. Provide fast-acting carbohydrate (regular soft drink or fruit juice) 1
2. Follow with long-acting carbohydrate (crackers with cheese or meat sandwich) 1
3. Initiate continuous IV dextrose if in hospital setting for sulfonylurea overdose 3
4. Monitor blood glucose frequently for at least 24 hours due to risk of recurrent hypoglycemia 3